Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Barx2 CRISPR Activation Plasmid (h): sc-403458-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Barx2 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Barx2 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Barx2 CRISPR Activation Plasmid (h) and Barx2 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the BARX2 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Barx2 Antibody (8A7/1): sc-53177
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Barx2 CRISPR Activation Plasmid (h) | sc-403458-ACT | 20 µg | $397.00 |
Human BARX2 encodes Barx2, a homeobox transcription factor that regulates cell fate decisions and differentiation programs during development and tissue remodeling. Through sequence-specific DNA binding, Barx2 helps coordinate transcriptional networks linked to epithelial–mesenchymal interactions, cytoskeletal organization, and extracellular matrix regulation, influencing processes such as migration and lineage specification. BARX2 activity interfaces with broader developmental signaling axes that shape morphogenesis and cellular plasticity, making it relevant to studies of differentiation, regeneration, and dysregulated transcriptional control. Altered BARX2 expression has been reported across contexts of aberrant tissue architecture and proliferative disease biology, supporting its utility as a mechanistic node for transcriptional pathway interrogation.
Barx2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous BARX2 expression without altering the underlying DNA sequence.
Barx2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the BARX2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the BARX2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Barx2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native BARX2 locus and enabling the study of Barx2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Barx2 pathway restoration in tumor cells with silenced or reduced BARX2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.